Want to see HK:6118 full AI Analyst Report?
Austar Lifesciences Ltd. (6118) AI Stock Analysis
Top Page
Austar Lifesciences Ltd.
(HKEX:6118)
The score is driven mainly by improving fundamentals (return to profitability, healthier leverage, and positive operating/free cash flow) and a relatively low P/E valuation. These positives are tempered by weak technical positioning (below key moving averages with slightly negative MACD) and still-thin margins with uneven revenue growth.
Austar Lifesciences Ltd. (6118) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 266.54M
- Dividend Yield
- ―
- Average Volume (3M)
- 71.79K
- Price to Earnings (P/E)
- 13.2
- Beta (1Y)
- 0.83
- Revenue Growth
- 14.04%
- EPS Growth
- -49.19%
- Country
- Hong Kong
- Employees
- 1,468
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Austar Lifesciences Ltd. Business Overview & Revenue Model
Company Description
Austar Lifesciences Limited functions as an investment holding company, delivering integrated engineering and technology solutions to pharmaceutical production facilities and research institutions globally, with a significant presence in Mainland Chi...
How the Company Makes Money
Austar Lifesciences Ltd. generates revenue primarily by selling products and delivering services to customers in the life sciences and biopharmaceutical ecosystem. Key revenue streams typically include (1) distribution and sales of laboratory and bio...
Austar Lifesciences Ltd. Financial Statement Overview
Summary
Profitability has rebounded from the 2023 loss, with 2025 net income rising to ~33.0M and EBIT/EBITDA turning positive again. Balance sheet leverage is manageable and improved (debt-to-equity ~0.42), while operating cash flow (~128.2M) and free cash flow (~99.7M) are positive. Offsetting this, revenue growth has been uneven and margins remain thin (net margin ~2.2% in 2025), and cash flows were volatile historically.
Income Statement
54NeutralBalance Sheet
66PositiveCash Flow
58Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.60B | 1.53B | 1.50B | 1.76B | 2.16B | 2.02B |
| Gross Profit | 290.37M | 293.27M | 301.22M | 336.05M | 488.80M | 479.01M |
| EBITDA | 77.75M | 92.28M | 87.88M | 25.15M | 159.79M | 148.54M |
| Net Income | 17.15M | 33.80M | 16.08M | -113.47M | 87.46M | 277.30M |
Balance Sheet | ||||||
| Total Assets | 2.14B | 2.13B | 2.08B | 2.16B | 2.39B | 2.04B |
| Cash, Cash Equivalents and Short-Term Investments | 255.32M | 276.59M | 167.81M | 173.76M | 148.13M | 219.74M |
| Total Debt | 268.24M | 343.82M | 401.95M | 496.20M | 336.55M | 155.22M |
| Total Liabilities | 1.31B | 1.30B | 1.29B | 1.38B | 1.51B | 1.26B |
| Stockholders Equity | 831.23M | 822.90M | 791.41M | 773.01M | 896.94M | 786.58M |
Cash Flow | ||||||
| Free Cash Flow | 152.42M | 99.74M | 78.31M | -133.59M | -155.25M | -204.02M |
| Operating Cash Flow | 186.17M | 128.24M | 98.81M | -62.65M | -37.93M | -103.45M |
| Investing Cash Flow | -35.54M | -15.58M | 4.43M | -54.47M | -153.14M | 65.02M |
| Financing Cash Flow | -93.12M | -42.76M | -101.32M | 147.12M | 125.30M | 59.35M |
Austar Lifesciences Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6118, the sentiment is Negative. The current price of 0.52 is below the 20-day moving average (MA) of 0.64, below the 50-day MA of 0.69, and below the 200-day MA of 0.75, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 18.78 is Positive, neither overbought nor oversold. The STOCH value of 14.81 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6118.
Austar Lifesciences Ltd. Peers Comparison
Overall Rating
HK:161267Neutral- HK:611857Neutral
HK:229746Neutral
HK:217045Neutral
HK:221644Neutral
HK:250044Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:1612 | 67Neutral | HKD 468.67M | 4.77 | 13.95% | 6.48% | 10.95% | 9.26% |
| HK:6118 | 57Neutral | HKD 266.54M | 13.17 | 2.07% | ― | 14.04% | -49.19% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2297 | 46Neutral | HKD 241.03M | -2.97 | -19.46% | ― | 4.35% | 43.23% |
| HK:2170 | 45Neutral | HKD 374.73M | -1.83 | -19.34% | ― | -2.28% | 24.76% |
| HK:2216 | 44Neutral | HKD 306.67M | -1.98 | -12.45% | ― | ― | ― |
| HK:2500 | 44Neutral | HKD 432.19M | -0.78 | -28.24% | ― | -38.15% | 25.70% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6118 | Austar Lifesciences Ltd. | 0.52 | -0.56 | -51.85% | |
| HK:1612 | Vincent Medical Holdings Limited | 0.71 | -0.10 | -12.24% | |
| HK:2170 | Suzhou Basecare Medical Corp. Ltd. Class H | 1.37 | -1.16 | -45.85% | |
| HK:2216 | Broncus Holding Corp. | 0.58 | -2.00 | -77.52% | |
| HK:2297 | Rainmed Medical Limited | 0.17 | -0.12 | -40.69% | |
| HK:2500 | Venus Medtech (Hangzhou), Inc. Class H | 0.98 | -1.77 | -64.36% |
Austar Lifesciences Ltd. Corporate Events
Austar Lifesciences Grows Revenue but Interim Profit Slides on Margin Pressure
Austar Lifesciences reported unaudited interim results for the six months ended 30 June 2026 showing revenue rising to RMB744.5 million from RMB661.9 million a year earlier, but gross profit slipped slightly to RMB138.1 million as the margin narrowed...
Austar Lifesciences Sets Board Meeting to Review Interim Results and Dividend
Austar Lifesciences Limited has announced that its board of directors will meet on 25 August 2026 to review and approve the group’s unaudited interim results for the six months ended 30 June 2026. At the same meeting, the board will also consid...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026